BioMarin Advances VOXZOGO Toward Full FDA Approval

1. Jordan Nova wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
2. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
3. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

The skeletal dysplasia market is expanding rapidly as diagnostic tools improve and targeted therapies gain traction, creating a clear opening for companies with proven assets in rare genetic bone disorders.

BioMarin Pharmaceuticals Inc. (BMRN:NASDAQ) stands out because its VOXZOGO therapy already treats thousands of children worldwide and now moves closer to full traditional approval.

Why BioMarin Holds a Leading Position

VOXZOGO received accelerated approval in 2021, and the latest supplemental New Drug Application acceptance by the FDA confirms the therapy rests on the largest clinical evidence package assembled for any achondroplasia treatment, according to a July 13 release. The company has compiled multi-year safety and efficacy results from three ongoing extension studies that demonstrate gains in growth velocity, body proportionality, and arm span.

Key Investor Takeaways

• VOXZOGO is the only approved therapy for achondroplasia that can start at birth and has already reached more than 5,000 patients in over 50 countries.
• The FDA set a PDUFA target action date of Feb. 28, 2027, for the supplemental application seeking traditional approval.
• Long-term data from ongoing studies support conversion from accelerated to full approval, satisfying post-marketing requirements.
• Positive Phase 3 results in hypochondroplasia could expand the addressable patient population significantly.
• Analysts see BioMarin maintaining a competitive edge while the broader skeletal dysplasia market grows at an 8.1% CAGR through 2035.
• Institutional ownership near 95% reflects strong professional investor interest in the company's rare-disease pipeline.

Unique Mechanism and Expanding Opportunity

VOXZOGO works as a C-type natriuretic peptide analog that stimulates endochondral bone growth downstream of the mutated FGFR3 gene. Achondroplasia is the most common form of skeletal dysplasia that causes disproportionate short stature. More than 80% of cases occur spontaneously in children born to average-height parents, and the condition affects roughly one in 25,000 births globally.

Industry Timing and Growth Drivers

The global skeletal dysplasia market stood at US$3.2 billion in 2025 and is forecast to reach US$6.9 billion by 2035, advancing at an 8.1% compound annual growth rate, according to a report by Vantage Market Research. Parallel expansion in the broader genetic disorders market, projected to exceed US$50 billion by 2033 at a 12.24% CAGR, according to BioSpace, underscores rising demand for precision therapies in this space.

Analyst Perspectives and Valuation

H.C. Wainwright maintains a Neutral rating and US$50 price target, noting that full approval would not materially alter the competitive landscape, yet still validates the therapy's long-term data package.

Wedbush rates the shares Outperform with a US$94 target, citing stronger-than-expected growth velocity gains in hypochondroplasia that could open a market more than ten times larger than current indications.

Share Structure and Upcoming Milestones

BioMarin holds a market capitalization of CA$11.52 billion with 193.28 million shares outstanding. ¹Institutions control 95% of the float while insiders hold nearly 2%. The next major catalyst remains the February 2027 PDUFA decision.

Retail investors should monitor quarterly patient-start trends, persistence rates, and any competitive pressure from emerging programs while recognizing that BioMarin continues to build the most comprehensive clinical dataset in the field.

Common Questions from Investors

What did the FDA do? It accepted BioMarin's supplemental New Drug Application seeking full (traditional) approval of VOXZOGO for children with achondroplasia.

When will the FDA decide? The PDUFA target action date is Feb. 28, 2027.

What is achondroplasia? The most common form of skeletal dysplasia, causing disproportionate short stature, is caused by an FGFR3 gene mutation. It occurs in about 1 in 25,000 births, and over 80% of cases arise spontaneously in children of average-height parents.

What's the market opportunity? The global skeletal dysplasia market is projected to grow from US$3.2B (2025) to US$6.9B by 2035 (8.1% CAGR).